[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100055349":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":7,"collaborators":7,"id":14,"slug":15,"hasResults":16,"nctId":17,"briefTitle":18,"officialTitle":19,"acronym":7,"eligibilityCriteria":20,"healthyVolunteers":16,"sex":21,"minAge":22,"maxAge":7,"enrollmentInfo":23,"targetDuration":7,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":7,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":7,"completionDateStruct":36,"leadSponsor":38,"locationsCount":7},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Indinavir sulfate",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Zidovudine","100055349","the-safety-and-effectiveness-of-mk-639-and-zidovudine-used-alone-and-together-in-hiv-infected-patients-who-have-never-taken-anti-hiv-drugs-100055349",false,"NCT00002443","The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","Twelve-Month Study in HIV-1 Seropositive Retroviral-Naive Patients to Compare the Safety and Efficacy of MK-639 and Zidovudine (AZT) Administered Concomitantly to MK-639 Alone and Zidovudine (AZT) Alone","Inclusion Criteria\n\nPatients must have:\n\n* HIV seropositivity.\n* Average CD4 count between 50 and 500 cells\u002Fmm3 based on 2 separate pre-study determinations at least 1 week apart.\n\nNote:\n\n* Patients with known hemophilia may be enrolled at the discretion of the investigator.\n\nPrior Medication:\n\nExcluded:\n\n* Any protease inhibitor.\n* Significant prior use (greater than 2 weeks) of nucleoside analogues.\n* Chronic therapy for an active opportunistic infection. (Allowed:\n* Prophylaxis with aerosolized pentamidine, trimethoprim\u002Fsulfamethoxazole, dapsone, topical antifungals, and isoniazid).\n* Investigational agents or immunomodulators within 30 days prior to study entry.\n\nExclusion Criteria\n\nCo-existing Condition:\n\nPatients with the following symptoms or conditions are excluded:\n\n* Acute hepatitis.\n* Lymphoma.\n* Visceral Kaposi's sarcoma.\n* Invasive cervical cancer.\n* Active infection.\n\nConcurrent Medication:\n\nExcluded:\n\nAnticipated immunosuppressive therapy.","ALL","18 Years",{"count":24,"type":7},780,"INTERVENTIONAL",[27],"NA","To compare the effects on CD4 counts and safety of MK-639 (indinavir, IDV) and AZT administered concomitantly to MK-639 alone and AZT alone in HIV-1 seropositive patients.",[30],"HIV Infections","COMPLETED","2005-06-23",{"date":34,"type":35},"2005-06-24","ESTIMATED",{"date":37,"type":7},"1996-01",{"name":39,"class":6},"Merck Sharp & Dohme LLC"]